Latest Market Entry News

Page 5 of 56
ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.
Ada Torres
Ada Torres
6 Aug 2026
Clarity Pharmaceuticals has presented compelling clinical evidence that its investigational 64Cu-SAR-bisPSMA diagnostic and 67Cu-SAR-bisPSMA therapeutic candidates outperform current standards in prostate cancer care, positioning the company for regulatory and commercial milestones.
Ada Torres
Ada Torres
6 Aug 2026
Acrux Limited spotlighted its Female Testosterone Metered Dose Transdermal System (MDTS) at the Bioshares Biotech Summit, revealing positive Phase II data and outlining a clear regulatory and commercial roadmap targeting Hypoactive Sexual Desire Disorder (HSDD) in women.
Ada Torres
Ada Torres
6 Aug 2026
Memphasys secures exclusive Felix™ commercialisation agreement in Poland, marking its third European market entry with a two-year contract valued at approximately A$350,000.
Ada Torres
Ada Torres
5 Aug 2026
Clarity Pharmaceuticals bolsters its commercial readiness with a $178.3 million cash reserve and a key US manufacturing agreement, while clinical trials for its prostate cancer imaging and therapeutic agents progress with promising data.
Ada Torres
Ada Torres
31 July 2026
1414 Degrees secured $8.45 million funding and inked major agreements to commercialise its SiNTL battery technology across AI data centres, drones, satellites and defence sectors.
Victor Sage
Victor Sage
31 July 2026
OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.
Ada Torres
Ada Torres
30 July 2026
BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.
Ada Torres
Ada Torres
30 July 2026
Streamplay Studio Limited has reported its fifth straight quarter of positive operating cash flow, driven by strong customer receipts and strategic publishing deals. The company is advancing multiple game releases and expanding its cloud gaming footprint across new regions.
Sophie Babbage
Sophie Babbage
30 July 2026
Sprintex boosted its commercial footprint in the June quarter with a 65% order book increase from Mest Water, a paid trial at Taiwan's TSMC, and Dutch regulatory clearance lifting key uncertainties.
Victor Sage
Victor Sage
30 July 2026
Cleo Diagnostics has entered the critical Analytical Validation phase for its ovarian cancer blood test, progressing toward an FDA 510(k) submission targeted for the first half of 2027. The company also secured a U.S. reimbursement pathway to support early market entry post-clearance, backed by a cash balance of A$6.2 million.
Ada Torres
Ada Torres
29 July 2026
De.mem Limited posted its second highest quarterly cash receipts of approximately $9.6 million for June 2026, marking 29 consecutive quarters of growth and positive operating cash flow of $424k. The company’s strong half-year performance is underpinned by recurring revenues, a robust Western Australian business, and record results from its German subsidiary.
Victor Sage
Victor Sage
29 July 2026

Browse the archive

Full archive